drugset / Trial / NCT03436199
Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study assessed the efficacy and safety of ADS-5102 (at daily doses of 137 mg or 274 mg) compared with placebo in MS patients with walking impairment.
Timeline
- Start
- 2018-03-29
- Primary completion
- 2019-12-10
- Completion
- 2019-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amantadine | Unknown | 137 mg | Oral |
| Subject | Amantadine | Unknown | 274 mg | Oral |